MABEL Fund

MABEL: an academic research programme exploring the market environment of biologics incl biosimilars following loss off exclusivity @KU_Leuven 🧬

[ISPOR @ISPORorg]

The ISPOR Biosimilars Special Interest Group (SIG) published a new article, titled “Opening Up a Discussion on Biosimilar Value Assessment”, in the March/April 2023 issue of Value & Outcomes Spotlight. View it here: https://t.co/VMBAtnllnA #HEOR #biosimilars #valueassessment

[Liese Barbier @LieseBarbier]

Very much looking forward to speak at the European Commission’s Multistakeholder Event on #Biosimilar Medicines, next week Tue 13/12! 🇪🇺
More info and registration via link 👇

https://t.co/eH1qYfrVIR

#competition #sustainability #interchangeability @MABELFund @PharmaKULeuven

[MABEL Fund @MABELFund]

The MABEL Team is excited to be attending #isporeurope in #Vienna! Join us at the poster sessions featuring biosimilars-related research from the KU Leuven PhD researchers Elif Car, Yannick Vandenplas, Teresa Barcina Lacosta.
https://t.co/8B7zxggCkH #MabelFund #biosimilars

[Marta Baldrighi @m_baldri]

The benefits deriving from purchasing best-value biologics can and should be transformed into tangible improvements for patients and the healthcare community.

#BIOS22
@medicinesforEU

[Liese Barbier @LieseBarbier]

An important day for #biosimilars! This EMA/HMA joint statement on biosimilar #interchangeability is a huge step forward in building trust in biosimilars and harmonizing the #regulatory message on biosimilars in the EU! #onevoice #EMA #NCAs #regulatoryconvergence

[MABEL Fund @MABELFund]

New paper alert! Pharmaceutical policies are generally based on the assumption that involved stakeholders make rational decisions. https://t.co/TvcjlSbw3N
#behavioraleconomics #healthpolicy #policymaking #biologicals #offpatentbiologicals #healthcare #research #mabelfund

[Encarna Cruz Martos @EncarnaCruzM]

Artículo firmado por investigadores de la Universidad de Leuven @LieseBarbier (Bélgica) con recomendaciones para implantar una política de promoción de #Biosimilares. La metodología: Técnica de Grupo Nominal.
Las acciones de mayor grado de consenso y alta prioridad son👇

[MABEL Fund @MABELFund]

Barbier and colleagues assessed the #biosimilar landscape from the healthcare professionals’ perspective in Belgium and present in this paper consensus-developed policy recommendations to improve biosimilar use and switch decision-making. https://t.co/BcEr7DiWZc #biosimilars

[Frontiers - Pharmacology and Toxicology @FrontPharmacol]

New Research: Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking https://t.co/jrb4GJYiQj #pharmacology

[Liese Barbier @LieseBarbier]

New paper alert! Interested to learn more about the Belgian biosimilar landscape and concrete ways to improve #biosimilaruse and #switching? Read the full text here ⏩ https://t.co/HkW6XbUex7 

#biosimilars #policymaking #offpatentbiologicals #research #healthpolicy @MABELFund

[MABEL Fund @MABELFund]

US #spending on prescription drugs has risen substantially in the past 20 years. A major #driver of this growth is the use of #high-priced #biologicals.

The full text Editorial:
https://t.co/fHW5x4PnSY.

The paper of Jensen and colleagues:
https://t.co/SS6YhvOH7c

#biosimilars

[Liese Barbier @LieseBarbier]

Are you interested in pursuing a PhD at the intersection of Regulatory Science, Health Policy and Patient Engagement at the KU Leuven in Belgium? Click on the link below! Our unit is hiring a PhD researcher who will conduct patient preference research. Come join our dynamic team!

[Teresa Barcina Lacosta @BarcinaTeresa]

The @ISPORorg Biosimilar SIG is presenting a Forum on "The Evolution of #Biosimilar Markets: Key Elements for Long-Term #Sustainability of the Health Care Ecosystem”.

Join us on Tuesday May 17 @ 11:45 AM!
More information here: https://t.co/MEepITkS9p

#ISPORAnnual #HEOR

[MABEL Fund @MABELFund]

OVERVIEW OF EU APPROVED #BIOSIMILARS – update as of 12 April 2022 (based on CHMP 21-24 March 2022 meeting)

More information and product overviews are accessible via the links: https://t.co/t0ANQhBKOA, https://t.co/75eFUnD47I, https://t.co/bebBKNeKux, https://t.co/WPcR2W3hRV

[MABEL Fund @MABELFund]

Barbier and colleagues have investigated how #regulators on pan-European and national level provide information and guidance to #stakeholders on #biosimilars and their use, with a focus on #interchangeability, #switching and #substitution.
https://t.co/SjheN0UYI2

[BioSim @BioSim_es]

🟢Existe una oportunidad de ampliar la información a nivel nacional y aprovechar más activamente los materiales de información desarrollados por la UE.
🟩Para saber más 👇https://t.co/CLffmWRwxj

[Encarna Cruz Martos @EncarnaCruzM]

Interesante estudio sobre la información que proporcionan las agencias regulatorias de medicamentos en Europa sobre biosimilares.

"Only less than half of national medicines agencies provided guidance on biosimilar interchangeability and switching (8/31 and 12/31, respectively)"

[MABEL Fund @MABELFund]

Interested in reading about our learnings on benefit-sharing programs? The full content is accessible via the link: https://t.co/Vz9c1AbXBX
#BioDrugs #biosimilars #benefitsharing #gainsharing #bestvalue #qualityofcare #pharmaceuticals #policymaking #healthcare #mabelfund

[MABEL Fund @MABELFund]

The meanings and use of terminology regarding #Interchangeability of innovator #biologics and #biosimilars change depending on the country. This has caused confusion among the #healthcare community.
https://t.co/liYJZyDYHM
#mabelfund #biosimilarinterchangeability

[MABEL Fund @MABELFund]

Monoclonal antibodies (#mAbs) have been used in the clinical practice for over 30 years. These products have considerably advanced #care for #patients diagnosed with severe conditions, such as #cancer ...
https://t.co/swo1u36sRB